Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 66.7%High 1 · 33.3%

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

All‐cause mortality · pulmonary arterial hypertension

Group 1 Pulmonary arterial hypertension ‐ PDE5i showed no clear difference in mortality compared with placebo, on combination therapy (moderate certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 0.26 [0.07, 1.06]
3 studies · 492 participants
Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERA

All‐cause mortality · pulmonary arterial hypertension

Group 1 Pulmonary arterial hypertension ‐ PDE5i showed no clear difference in mortality compared with ERA (moderate certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 3.19 [0.74, 13.64]
2 studies · 272 participants
Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

All‐cause mortality · pulmonary arterial hypertension

Group 1 Pulmonary arterial hypertension ‐ PDE5i leads to lower mortality compared with placebo (high certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 0.22 [0.07, 0.68]
8 studies · 1119 participants
High